1. Home
  2. MRKR vs JZ Comparison

MRKR vs JZ Comparison

Compare MRKR & JZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MRKR
  • JZ
  • Stock Information
  • Founded
  • MRKR N/A
  • JZ 2011
  • Country
  • MRKR United States
  • JZ China
  • Employees
  • MRKR N/A
  • JZ N/A
  • Industry
  • MRKR Biotechnology: Pharmaceutical Preparations
  • JZ Other Consumer Services
  • Sector
  • MRKR Health Care
  • JZ Real Estate
  • Exchange
  • MRKR Nasdaq
  • JZ Nasdaq
  • Market Cap
  • MRKR 16.1M
  • JZ 26.7M
  • IPO Year
  • MRKR N/A
  • JZ 2022
  • Fundamental
  • Price
  • MRKR $1.18
  • JZ $0.92
  • Analyst Decision
  • MRKR Strong Buy
  • JZ
  • Analyst Count
  • MRKR 2
  • JZ 0
  • Target Price
  • MRKR $13.50
  • JZ N/A
  • AVG Volume (30 Days)
  • MRKR 239.7K
  • JZ 6.2K
  • Earning Date
  • MRKR 03-25-2025
  • JZ 09-27-2024
  • Dividend Yield
  • MRKR N/A
  • JZ N/A
  • EPS Growth
  • MRKR N/A
  • JZ N/A
  • EPS
  • MRKR N/A
  • JZ N/A
  • Revenue
  • MRKR $5,395,849.00
  • JZ $50,810,288.00
  • Revenue This Year
  • MRKR $195.40
  • JZ N/A
  • Revenue Next Year
  • MRKR N/A
  • JZ N/A
  • P/E Ratio
  • MRKR N/A
  • JZ N/A
  • Revenue Growth
  • MRKR 79.04
  • JZ N/A
  • 52 Week Low
  • MRKR $1.13
  • JZ $0.53
  • 52 Week High
  • MRKR $5.99
  • JZ $2.35
  • Technical
  • Relative Strength Index (RSI)
  • MRKR 33.38
  • JZ 48.85
  • Support Level
  • MRKR $1.35
  • JZ $0.81
  • Resistance Level
  • MRKR $1.99
  • JZ $0.99
  • Average True Range (ATR)
  • MRKR 0.22
  • JZ 0.11
  • MACD
  • MRKR 0.01
  • JZ -0.01
  • Stochastic Oscillator
  • MRKR 5.21
  • JZ 42.31

About MRKR Marker Therapeutics Inc.

Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and innovative peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from its MultiTAA T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets. It is also developing peptide-based immunotherapeutic vaccines for the treatment of metastatic solid tumors, as well as PolyStart.

About JZ Jianzhi Education Technology Group Company Limited

Jianzhi Education Technology Group Co Ltd engages in developing educational content to fulfill the massive demand for high-quality, professional development training resources in China. The company and its subsidiaries VIE and VIEs generate subscription revenue through selling subscriptions to online learning platforms, higher education institutions, and other institutional customers under a B2B2C model mainly through the platform of Sentu Academy; offering subscriptions concerning educational content in mobile video packages directly to end users under a B2C model through the platforms such as Fish Learning or Light Class, etc. It has two operating segments: Educational content services and other services and IT-related solution services.

Share on Social Networks: